Trending
Jim Keller's Tenstorrent Raises $1.5 Billion at a $6.2 Billion Valuation to Challenge Nvidia With Open RISC-V ChipsAmazon Launches TorchNeuron, Free Software That Lets AI Developers Switch to Its Chips With One Change, to Loosen Nvidia's GripTradeweb to Buy Bond Trading Platform Trumid for $1.97 Billion as Electronic Credit Markets ConsolidateStarlink, Jio and OneWeb All Hold Licences, Yet None Can Sell Satellite Internet in India. Inside the Satcom QueueMicrosoft Pulls Out of UK AI Data Centre Deal Amid Power DelaysBitcoin Reclaims $82,500 After Last Week's Slide, but ETF Outflows and Fed Uncertainty Cloud the ReboundJim Keller's Tenstorrent Raises $1.5 Billion at a $6.2 Billion Valuation to Challenge Nvidia With Open RISC-V ChipsAmazon Launches TorchNeuron, Free Software That Lets AI Developers Switch to Its Chips With One Change, to Loosen Nvidia's GripTradeweb to Buy Bond Trading Platform Trumid for $1.97 Billion as Electronic Credit Markets ConsolidateStarlink, Jio and OneWeb All Hold Licences, Yet None Can Sell Satellite Internet in India. Inside the Satcom QueueMicrosoft Pulls Out of UK AI Data Centre Deal Amid Power DelaysBitcoin Reclaims $82,500 After Last Week's Slide, but ETF Outflows and Fed Uncertainty Cloud the Rebound
Shanghai AI Drug-Discovery Firm Nutshell Therapeutics Closes Series C1 Round

Shanghai AI Drug-Discovery Firm Nutshell Therapeutics Closes Series C1 Round

Artificial Intelligence

Shanghai AI Drug-Discovery Firm Nutshell Therapeutics Closes Series C1 Round

Nutshell Therapeutics, also known as Yudao Bio, a Shanghai-based AI biotechnology and drug discovery firm, has closed a Series C1 funding round backed by Trustbridge Capital, Decheng Capital and other investors.

Aravind Kumar

Author

The Chronological Feed

Sorted by: Latest